Q1 EPS Estimates for Aktis Oncology Boosted by HC Wainwright

Aktis Oncology (NASDAQ:AKTS) – Stock analysts at HC Wainwright upped their Q1 2026 earnings per share (EPS) estimates for shares of Aktis Oncology in a research report issued to clients and investors on Tuesday, March 31st. HC Wainwright analyst R. Burns now forecasts that the technology company will post earnings per share of ($0.36) for the quarter, up from their prior estimate of ($0.64). HC Wainwright has a “Buy” rating and a $33.00 price objective on the stock. The consensus estimate for Aktis Oncology’s current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Aktis Oncology’s Q2 2026 earnings at ($0.38) EPS, Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.51) EPS, FY2026 earnings at ($1.72) EPS and FY2027 earnings at ($2.35) EPS.

A number of other research firms also recently issued reports on AKTS. Bank of America assumed coverage on shares of Aktis Oncology in a research report on Tuesday, February 3rd. They issued a “buy” rating and a $34.00 target price for the company. Leerink Partners assumed coverage on Aktis Oncology in a research note on Tuesday, February 3rd. They issued an “outperform” rating and a $31.00 target price on the stock. JPMorgan Chase & Co. started coverage on Aktis Oncology in a research report on Tuesday, February 3rd. They issued an “overweight” rating and a $30.00 target price on the stock. Wall Street Zen raised Aktis Oncology to a “hold” rating in a research note on Saturday, January 17th. Finally, TD Cowen initiated coverage on Aktis Oncology in a report on Tuesday, February 3rd. They issued a “buy” rating on the stock. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat, Aktis Oncology has an average rating of “Buy” and a consensus price target of $32.00.

Aktis Oncology Stock Up 1.8%

AKTS stock opened at $17.37 on Thursday. The stock’s 50 day moving average is $19.03. Aktis Oncology has a 52 week low of $14.72 and a 52 week high of $29.16.

Insider Activity

In related news, Director Helen Susan Kim purchased 835,000 shares of the firm’s stock in a transaction dated Monday, January 12th. The stock was bought at an average price of $18.00 per share, for a total transaction of $15,030,000.00. Following the purchase, the director owned 5,671,825 shares in the company, valued at $102,092,850. The trade was a 17.26% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Vida Ventures Ii, Llc bought 835,000 shares of Aktis Oncology stock in a transaction that occurred on Monday, January 12th. The stock was bought at an average price of $18.00 per share, with a total value of $15,030,000.00. Following the completion of the acquisition, the insider owned 5,671,825 shares in the company, valued at approximately $102,092,850. The trade was a 17.26% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders acquired 6,117,776 shares of company stock valued at $110,119,968. Corporate insiders own 3.30% of the company’s stock.

Aktis Oncology News Summary

Here are the key news stories impacting Aktis Oncology this week:

• Positive Sentiment: HC Wainwright raised earnings estimates across 2026 and 2027 quarters and kept a “Buy” rating with a $33 price target — the analyst materially reduced expected losses for Q1–Q4 2026 (e.g., Q1: from ($0.64) to ($0.36); Q2: ($0.71) to ($0.38); Q3: ($0.77) to ($0.46); Q4: ($0.83) to ($0.51)) and lifted FY2026 and FY2027 loss estimates (FY2026: ($2.95) to ($1.72); FY2027: ($3.71) to ($2.35)). That optimism is likely driving buying interest. Aktis Oncology (NASDAQ:AKTS) Stock Price Expected to Rise, HC Wainwright Analyst Says
• Positive Sentiment: Aktis announced FDA clearance of investigational new drug (IND) applications for AKY-2519 and provided business updates and full‑year 2025 financial results — IND clearances are a clear clinical development catalyst that can increase the stock’s upside if trials progress on schedule. Aktis Oncology Announces FDA Clearance of INDs for AKY-2519
• Neutral Sentiment: Market data and coverage references (e.g., Barron’s stock page) provide third‑party visibility but add no immediate catalyst; useful for background research. Aktis Oncology Inc. — Barron’s
• Negative Sentiment: Despite upgrades and IND clearance, consensus fundamentals remain loss-making (current full‑year consensus ≈ ($0.43) EPS) and the stock trades below its 50‑day moving average—ongoing development risk, cash burn and execution risk could pressure the share price if clinical or financing developments disappoint.

About Aktis Oncology

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.